Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581344 | 0.89 | GAA (0.51) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL12605638 | 0.86 | NAAA (0.46) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL30497634 | 0.86 | GAA (0.49) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL23199587 | 0.85 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL2575225 | 0.85 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL4282204 | 0.85 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL4282209 | 0.85 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL13387564 | 0.84 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL4719490 | 0.84 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL27234114 | 0.83 | EPHX1 (0.42) | GAAMAPK1HTTSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | GAA 96/4885MAPK1 4052/4885HTT 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.